The Drug Development Process > Phase II clinical trials with Reldesemtiv in Patients with Spinal Muscular Atrophy (SMA II-III)

presented in an oral presentation by John W. Day, MD, Ph.D., Professor of Neurology and Paediatrics (Genetics), Stanford University. This hypothesis-generating study met its primary goal. It fulfills the effect and safety profile. In collaboration with Astellas, Cytokinetics is developing reldesemtiv as a potential treatment for people with SMA and… Att fortsätt läsa